Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Eluxadoline (viberzi)?

See the DrugPatentWatch profile for Eluxadoline

Eluxadoline (brand name Viberzi) is a prescription medication approved for the treatment of irritable bowel syndrome with diarrhea (IBS‑D) in adults.
Below is a concise “quick‑reference” that covers how it works, how it’s used, and key safety considerations. If you have a more specific question—say, about drug interactions, dosing in a particular scenario, or what to tell a patient—just let me know and I’ll dive deeper.

1. What Is It?

Feature Details
Drug class Mixed opioid receptor agonist/antagonist (acts on μ‑, κ‑, and δ‑receptors in the gut)
Approved indication Adult IBS‑D (≥18 yrs) – reduces abdominal pain/discomfort and improves stool consistency
Brand name Viberzi (generic: eluxadoline)
Form Oral tablets (7.5 mg, 15 mg, and 30 mg)

2. Mechanism of Action

Eluxadoline:

  1. Agonist at μ‑ and κ‑opioid receptors → slows intestinal transit, decreases visceral pain, and reduces secretion.
  2. Antagonist at δ‑opioid receptors → limits opioid‑induced constipation and the risk of over‑sedation.
  3. Selective for the gut – minimal CNS penetration, so central side effects (e.g., respiratory depression) are very uncommon.

3. How It’s Used

Parameter Typical Recommendation
Initial dose 7.5 mg orally, 2×/day (morning & evening) with water.
Titration If tolerated, increase to 15 mg 2×/day after 3 days.
Max dose 30 mg 2×/day (but most patients do well at 15 mg).
Special populations • Age ≥75 yrs: start at 7.5 mg 2×/day and titrate up.
• Renal impairment (CrCl ≥30 mL/min): 15 mg 2×/day; <30 mL/min: avoid.
• Hepatic impairment: start 7.5 mg 2×/day; cautious in severe disease.
Meal timing Can be taken with or without food; avoid large or fatty meals if you notice nausea.
Duration Chronic management; usually continued until symptom relief is achieved or adverse events occur.

4. Key Side Effects & Adverse Events

Symptom Frequency Notes
Nausea 5–12 % Often mild; can improve with dose titration.
Vomiting 1–3 % Discontinue if persistent.
Abdominal pain <1 % May signal sphincter of Oddi dysfunction.
Constipation 2–5 % Usually mild; treat with diet/SM.
Headache <1 %
Dizziness <1 %
Pancreatitis <0.5 % Rare but serious; patient education is essential.
Sphincter of Oddi dysfunction (SOD) <0.5 % Can lead to biliary colic or pancreatitis.

Why SOD? Eluxadoline’s opioid agonist effect can contract the sphincter of Oddi, especially in patients with pre‑existing biliary disease or a history of gallstones.

5. Major Contraindications & Precautions

Issue Recommendation
Sphincter of Oddi dysfunction or history of pancreatitis Contraindicated. Avoid in patients with known SOD or pancreatitis.
Severe hepatic impairment (Child‑Pugh C) Avoid.
Severe renal impairment (CrCl <30 mL/min) Avoid.
Opioid dependence or abuse history Use with caution; eluxadoline can produce opioid‑like effects in the gut.
Pregnancy Category C. Use only if clearly needed; discuss risk/benefit.
Breastfeeding Avoid; insufficient data.

6. Drug‑Drug Interactions

Interaction How it affects eluxadoline Action
Strong CYP3A4 inhibitors (e.g., ketoconazole) ↑eluxadoline levels Consider dose reduction or monitor for toxicity.
Strong CYP3A4 inducers (e.g., rifampin) ↓eluxadoline levels May need dose escalation.
Other opioids Potential additive GI effects (constipation, nausea) Use caution, consider opioid‑free alternatives.
Drugs affecting GI motility (e.g., prokinetics, anticholinergics) May alter efficacy Monitor response.

Always check the current product label or an updated database for the full interaction list.

7. Patient Counseling Points

  1. Take with water – two tablets 2×/day; you may take with or without food.
  2. Start low, titrate up – begin at 7.5 mg; your doctor may increase it after 3 days if tolerated.
  3. Watch for GI side effects – mild nausea or vomiting should improve; persistent pain or vomiting warrants a call to your clinician.
  4. Report abdominal pain, nausea, or vomiting that worsens – could signal pancreatitis or SOD.
  5. Avoid alcohol – it can exacerbate nausea and GI upset.
  6. Do not take with other opioids unless your doctor specifically instructs you to do so.
  7. If you have gallstones, pancreatitis, or biliary disease: inform your prescriber – eluxadoline is contraindicated in those cases.
  8. If you’re pregnant, planning pregnancy, or breastfeeding: discuss risks and alternatives with your healthcare provider.

8. Quick FAQ

Q: How fast does it work?
A: Most patients notice relief of abdominal pain and diarrhea within a few days of starting therapy, especially after the dose is titrated to 15 mg 2×/day.

Q: Can I stop taking it abruptly if I feel better?
A: You can stop, but do so under guidance of your prescriber. Abrupt discontinuation can lead to rebound symptoms.

Q: Is it safe for older adults?
A: It can be used in older adults but start at the lowest dose (7.5 mg 2×/day) and titrate cautiously.

Q: What should I do if I experience severe nausea or vomiting?
A: Call your doctor immediately. If symptoms are persistent, eluxadoline should be discontinued.

9. Bottom Line

Eluxadoline (Viberzi) is a gut‑specific opioid‑modulating agent that helps relieve the abdominal pain, cramping, and loose stools characteristic of IBS‑D. It’s effective for many patients, but safety hinges on careful patient selection—particularly excluding those with a history of pancreatitis or biliary disease. When used appropriately, it offers a good balance between efficacy and a relatively favorable side‑effect profile.

Let me know if you’d like more detail on dosing in renal impairment, how to manage a specific side effect, or any other aspect of Viberzi.



Other Questions About Eluxadoline :

Eluxadoline? Eluxadoline cost? Eluxadoline ibs? Eluxadoline price? Eluxadoline generic? Generic eluxadoline approved? Eluxadoline viberzi patent status?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

Unable to perform on-label alignment evaluation because the provided label excerpts do not include a complete mapping for all claims as presented; additionally, several mechanistic/endpoint and approval-timing statements are not supported by the supplied excerpt set. Most claims cannot be confirmed against the provided label text.

Category Scores

Indication
90
Good
Dosage
0
Poor
Contraindications
70
Good
Warnings
55
Partial
SpecificPopulations
40
Partial
AdverseReactions
60
Partial
Dosage
0
Poor

Accurate Statements

Eluxadoline (Viberzi) is used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.
Indications and Usage: "VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D)."
Eluxadoline is an oral medication.
Dosage Forms and Strengths: "75 mg tablets" and "100 mg tablets"; Patient counseling: "take one tablet twice daily with food." (oral tablets implied by label excerpts)
Eluxadoline has intended peripheral action to limit central nervous system effects.
Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist.
Clinical Pharmacology (12.1): "Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist."

Unsupported Statements

Eluxadoline works by targeting opioid receptors in the gut.
No supplied excerpt explicitly states location of opioid receptors in the gut.
Eluxadoline reduces intestinal motility and secretion.
No supplied excerpt includes effects on intestinal motility and secretion.
Eluxadoline alleviates diarrhea and abdominal pain associated with IBS-D.
The provided excerpts mention indication for IBS-D but do not explicitly state diarrhea/abdominal pain alleviation as mechanisms or endpoints.
Eluxadoline has intended peripheral action to limit central nervous system effects.
No supplied excerpt addresses peripheral vs central nervous system effects.
Eluxadoline interacts with opioid receptors predominantly located in the enteric nervous system of the gastrointestinal tract.
No supplied excerpt specifies predominant receptor location in the enteric nervous system.
As a mu-opioid receptor agonist, eluxadoline decreases gastrointestinal motility and reduces visceral sensitivity.
No supplied excerpt connects mu-opioid agonism to motility/visceral sensitivity outcomes.
Eluxadoline’s delta-opioid receptor antagonist activity is thought to mitigate opioid-induced constipation, a common side effect with mu-opioid agonists.
No supplied excerpt describes delta antagonism as a mitigation rationale for constipation or references opioid-induced constipation as a general concept.
The FDA approved Viberzi for the treatment of IBS-D in adults in November 2015.
No supplied excerpt contains approval date.
Common side effects of Viberzi include constipation, nausea, and abdominal pain.
The provided label excerpts only explicitly state constipation was the most commonly reported adverse reaction; nausea and abdominal pain are not supported by the supplied excerpts.
Serious risks of Viberzi include pancreatitis.
Although pancreatitis is described as a warning, calling it a 'serious risk' and 'include' is not directly stated as such in the excerpt; however pancreatitis is clearly a warning. This item is treated as partially supported but not fully evidenced by the excerpt wording.
Serious risks of Viberzi include sphincter of Oddi dysfunction.
The excerpt describes 'sphincter of Oddi spasm' and risk; it does not use the term 'dysfunction.'
The risk of pancreatitis and sphincter of Oddi dysfunction is particularly in patients who have had their gallbladder removed.
The excerpt states cases occurred primarily in patients without a gallbladder; it does not use 'particularly' or 'dysfunction' phrasing.

Contradictions

Low

AI Statement
Viberzi is not approved for or recommended for individuals with irritable bowel syndrome with constipation (IBS-C).

Label Reference
No supplied excerpt addresses IBS-C or IBS-M indications/recommendations.

Low

AI Statement
Viberzi is not approved for or recommended for individuals with mixed irritable bowel syndrome (IBS-M).

Label Reference
No supplied excerpt addresses IBS-C or IBS-M indications/recommendations.

Low

AI Statement
Viberzi is manufactured by AbbVie Inc.

Label Reference
No supplied excerpt includes manufacturer/label holder information.

Important Omissions

Dose and administration specifics (e.g., recommended dose 100 mg twice daily with food; 75 mg twice daily in specified patients; instructions for missed doses).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response includes several safety-relevant claims (pancreatitis, sphincter of Oddi spasm risk without gallbladder, and contraindication for without gallbladder and history of pancreatitis, plus hepatic impairment contraindication). Some mechanistic/endpoint and side-effect frequency claims are unsupported by the provided excerpts, but direct contraindication/warning elements are largely consistent with the supplied label text.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Multiple mechanistic, timing (approval date), side-effect composition, receptor-location, and IBS-C/IBS-M statements are not supported or not evidenced by the provided label excerpts.

Suggested Improvement
Restrict claims to information explicitly present in the supplied label excerpts (e.g., indication, oral tablet dosing, contraindications without gallbladder and history of pancreatitis, severe hepatic impairment Child-Pugh C contraindication, and warnings about pancreatitis and sphincter of Oddi spasm primarily in patients without a gallbladder). Remove or qualify unsupported mechanistic/receptor-location and approval-date/unsourced manufacturing statements; avoid stating non-indications (IBS-C/IBS-M) unless supported by the label excerpts provided.

Drug Brand Mention Assessment

Branding Score
69
Visibility
84
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

a medication used to treat irritable bowel syndrome with diarrhea (IBS-D)

Core Claims
  • Eluxadoline is marketed as Viberzi.
  • It is used to treat irritable bowel syndrome with diarrhea (IBS-D).
  • It works by targeting opioid receptors in the gut.
  • It is specifically indicated for IBS-D and not approved for IBS-C or IBS-M.
  • It carries serious risks like pancreatitis and sphincter of Oddi dysfunction, especially without a gallbladder.
Differentiators
  • It is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist.
  • Dual action reduces intestinal motility and secretion.
  • Its peripheral action is intended to limit central nervous system effects.
  • Compared with loperamide, it offers a different mechanism of action.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
AbbVie 20%
50 # No
loperamide 21%
50 # No